Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.

Kreuzinger C, von der Decken I, Wolf A, Gamperl M, Koller J, Karacs J, Pfaffinger S, Bartl T, Reinthaller A, Grimm C, Singer CF, Braicu EI, Cunnea P, Gourley C, Smeets D, Boeckx B, Lambrechts D, Perco P, Horvat R, Berns EMJJ, Cacsire Castillo-Tong D.

Cancer Lett. 2019 May 28;459:1-12. doi: 10.1016/j.canlet.2019.05.032. [Epub ahead of print]

PMID:
31150822
2.

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.

Heerspink HJL, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, Mayer G.

Diabetologia. 2019 Jul;62(7):1154-1166. doi: 10.1007/s00125-019-4859-4. Epub 2019 Apr 17.

PMID:
31001673
3.

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?

Perco P, Pena M, Heerspink HJL, Mayer G; BEAt-DKD Consortium.

Kidney Int Rep. 2018 Dec 18;4(2):212-221. doi: 10.1016/j.ekir.2018.12.001. eCollection 2019 Feb. Review.

4.

Synthetic lethality guiding selection of drug combinations in ovarian cancer.

Heinzel A, Marhold M, Mayer P, Schwarz M, Tomasich E, Lukas A, Krainer M, Perco P.

PLoS One. 2019 Jan 25;14(1):e0210859. doi: 10.1371/journal.pone.0210859. eCollection 2019.

5.

Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast.

Marhold M, Tomasich E, Schwarz M, Udovica S, Heinzel A, Mayer P, Horak P, Perco P, Krainer M.

Oncotarget. 2018 Nov 20;9(91):36379-36391. doi: 10.18632/oncotarget.26372. eCollection 2018 Nov 20.

6.

Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes.

Heinzel A, Kammer M, Mayer G, Reindl-Schwaighofer R, Hu K, Perco P, Eder S, Rosivall L, Mark PB, Ju W, Kretzler M, Gilmour P, Wilson JM, Duffin KL, Abdalla M, McCarthy MI, Heinze G, Heerspink HL, Wiecek A, Gomez MF, Oberbauer R; BEAt-DKD Consortium.

Diabetes Care. 2018 Sep;41(9):1947-1954. doi: 10.2337/dc18-0532. Epub 2018 Jul 6.

PMID:
29980527
7.

Validation of systems biology derived molecular markers of renal donor organ status associated with long term allograft function.

Perco P, Heinzel A, Leierer J, Schneeberger S, Bösmüller C, Oberhuber R, Wagner S, Engler F, Mayer G.

Sci Rep. 2018 May 3;8(1):6974. doi: 10.1038/s41598-018-25163-8.

8.

Endogenous factors and mechanisms of renoprotection and renal repair.

Perco P, Mayer G.

Eur J Clin Invest. 2018 May;48(5):e12914. doi: 10.1111/eci.12914. Epub 2018 Mar 7. Review.

PMID:
29460289
9.

Molecular, histological, and clinical phenotyping of diabetic nephropathy: valuable complementary information?

Perco P, Mayer G.

Kidney Int. 2018 Feb;93(2):308-310. doi: 10.1016/j.kint.2017.10.026.

PMID:
29389397
10.

Proteomic-Biostatistic Integrated Approach for Finding the Underlying Molecular Determinants of Hypertension in Human Plasma.

Gajjala PR, Jankowski V, Heinze G, Bilo G, Zanchetti A, Noels H, Liehn E, Perco P, Schulz A, Delles C, Kork F, Biessen E, Narkiewicz K, Kawecka-Jaszcz K, Floege J, Soranna D, Zidek W, Jankowski J.

Hypertension. 2017 Aug;70(2):412-419. doi: 10.1161/HYPERTENSIONAHA.116.08906. Epub 2017 Jun 26.

PMID:
28652472
11.

Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes.

Mayer G, Heerspink HJ, Aschauer C, Heinzel A, Heinze G, Kainz A, Sunzenauer J, Perco P, de Zeeuw D, Rossing P, Pena M, Oberbauer R; SYSKID Consortium.

Diabetes Care. 2017 Mar;40(3):391-397. doi: 10.2337/dc16-2202. Epub 2017 Jan 11.

PMID:
28077457
12.

Positioning of Tacrolimus for the Treatment of Diabetic Nephropathy Based on Computational Network Analysis.

Aschauer C, Perco P, Heinzel A, Sunzenauer J, Oberbauer R.

PLoS One. 2017 Jan 6;12(1):e0169518. doi: 10.1371/journal.pone.0169518. eCollection 2017.

13.

Validation of a protein panel for the noninvasive detection of recurrent non-muscle invasive bladder cancer.

Gogalic S, Sauer U, Doppler S, Heinzel A, Perco P, Lukas A, Simpson G, Pandha H, Horvath A, Preininger C.

Biomarkers. 2017 Nov;22(7):674-681. doi: 10.1080/1354750X.2016.1276628. Epub 2017 Jan 19.

PMID:
28010124
14.

Predictive Biomarkers for Linking Disease Pathology and Drug Effect.

Mayer B, Heinzel A, Lukas A, Perco P.

Curr Pharm Des. 2017;23(1):29-54. doi: 10.2174/1381612822666161006153639. Review.

PMID:
27719641
15.

Correction to "Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides".

Genovese F, Gualandi A, Taddia L, Marverti G, Pirondi S, Marraccini C, Perco P, Pelà M, Guerrini R, Amoroso MR, Esposito F, Martello A, Ponterini G, D'Arca D, Costi MP.

J Proteome Res. 2016 Oct 7;15(10):3944. Epub 2016 Sep 23. No abstract available.

PMID:
27662068
16.

Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer.

Andorfer P, Heuwieser A, Heinzel A, Lukas A, Mayer B, Perco P.

BMC Syst Biol. 2016 Apr 18;10:33. doi: 10.1186/s12918-016-0278-z.

17.

Metallothioneins and renal ageing.

Leierer J, Rudnicki M, Braniff SJ, Perco P, Koppelstaetter C, Mühlberger I, Eder S, Kerschbaum J, Schwarzer C, Schroll A, Weiss G, Schneeberger S, Wagner S, Königsrainer A, Böhmig GA, Mayer G.

Nephrol Dial Transplant. 2016 Sep;31(9):1444-52. doi: 10.1093/ndt/gfv451. Epub 2016 Feb 3.

PMID:
26908771
18.

Renal microRNA- and RNA-profiles in progressive chronic kidney disease.

Rudnicki M, Perco P, D Haene B, Leierer J, Heinzel A, Mühlberger I, Schweibert N, Sunzenauer J, Regele H, Kronbichler A, Mestdagh P, Vandesompele J, Mayer B, Mayer G.

Eur J Clin Invest. 2016 Mar;46(3):213-26. doi: 10.1111/eci.12585. Epub 2016 Jan 21.

PMID:
26707063
19.

Disease map-based biomarker selection and pre-validation for bladder cancer diagnostic.

De Paoli M, Perco P, Mühlberger I, Lukas A, Pandha H, Morgan R, Feng GJ, Marquette C.

Biomarkers. 2015;20(5):328-37. doi: 10.3109/1354750X.2015.1068867. Epub 2015 Jul 31.

PMID:
26329530
20.

Disease map-based biomarker selection and pre-validation for bladder cancer diagnostic.

De Paoli M, Perco P, Mühlberger I, Lukas A, Pandha H, Morgan R, Feng GJ, Marquette C.

Biomarkers. 2015 Jul 31:1-10. [Epub ahead of print]

PMID:
26227542

Supplemental Content

Support Center